298 related articles for article (PubMed ID: 16565470)
1. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
Esbenshade TA; Fox GB; Cowart MD
Mol Interv; 2006 Apr; 6(2):77-88, 59. PubMed ID: 16565470
[TBL] [Abstract][Full Text] [Related]
2. Histamine-selective H3 receptor ligands and cognitive functions: an overview.
Vohora D
IDrugs; 2004 Jul; 7(7):667-73. PubMed ID: 15243869
[TBL] [Abstract][Full Text] [Related]
3. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system.
Witkin JM; Nelson DL
Pharmacol Ther; 2004 Jul; 103(1):1-20. PubMed ID: 15251226
[TBL] [Abstract][Full Text] [Related]
4. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders.
Passani MB; Lin JS; Hancock A; Crochet S; Blandina P
Trends Pharmacol Sci; 2004 Dec; 25(12):618-25. PubMed ID: 15530639
[TBL] [Abstract][Full Text] [Related]
5. Keynote review: histamine H3 receptor antagonists reach out for the clinic.
Celanire S; Wijtmans M; Talaga P; Leurs R; de Esch IJ
Drug Discov Today; 2005 Dec; 10(23-24):1613-27. PubMed ID: 16376822
[TBL] [Abstract][Full Text] [Related]
6. The histamine H3 receptor: from gene cloning to H3 receptor drugs.
Leurs R; Bakker RA; Timmerman H; de Esch IJ
Nat Rev Drug Discov; 2005 Feb; 4(2):107-20. PubMed ID: 15665857
[TBL] [Abstract][Full Text] [Related]
7. H3 receptor antagonists/inverse agonists as anti-obesity agents.
Hancock AA
Curr Opin Investig Drugs; 2003 Oct; 4(10):1190-7. PubMed ID: 14649210
[TBL] [Abstract][Full Text] [Related]
8. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
Hancock AA
Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
[TBL] [Abstract][Full Text] [Related]
9. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D
Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
[TBL] [Abstract][Full Text] [Related]
10. Histamine H3 receptor antagonists: from target identification to drug leads.
Bonaventure P; Letavic M; Dugovic C; Wilson S; Aluisio L; Pudiak C; Lord B; Mazur C; Kamme F; Nishino S; Carruthers N; Lovenberg T
Biochem Pharmacol; 2007 Apr; 73(8):1084-96. PubMed ID: 17129577
[TBL] [Abstract][Full Text] [Related]
11. [Possible roles of brain histamine H3 receptors and the pharmacology of its ligands].
Onodera K; Watanabe T
Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Apr; 15(2):87-102. PubMed ID: 7796325
[TBL] [Abstract][Full Text] [Related]
12. Histamine H3 and H4 receptors as novel drug targets.
Tiligada E; Zampeli E; Sander K; Stark H
Expert Opin Investig Drugs; 2009 Oct; 18(10):1519-31. PubMed ID: 19758107
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of histamine H3 receptor antagonists in dementias.
Chazot PL
Drug News Perspect; 2010 Mar; 23(2):99-103. PubMed ID: 20369074
[TBL] [Abstract][Full Text] [Related]
14. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
Fox GB; Esbenshade TA; Pan JB; Radek RJ; Krueger KM; Yao BB; Browman KE; Buckley MJ; Ballard ME; Komater VA; Miner H; Zhang M; Faghih R; Rueter LE; Bitner RS; Drescher KU; Wetter J; Marsh K; Lemaire M; Porsolt RD; Bennani YL; Sullivan JP; Cowart MD; Decker MW; Hancock AA
J Pharmacol Exp Ther; 2005 Apr; 313(1):176-90. PubMed ID: 15608077
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists.
Dastmalchi S; Hamzeh-Mivehroud M; Ghafourian T; Hamzeiy H
J Mol Graph Model; 2008 Jan; 26(5):834-44. PubMed ID: 17561422
[TBL] [Abstract][Full Text] [Related]
17. Histamine H3 receptors and sleep-wake regulation.
Lin JS; Sergeeva OA; Haas HL
J Pharmacol Exp Ther; 2011 Jan; 336(1):17-23. PubMed ID: 20864502
[TBL] [Abstract][Full Text] [Related]
18. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease.
Brioni JD; Esbenshade TA; Garrison TR; Bitner SR; Cowart MD
J Pharmacol Exp Ther; 2011 Jan; 336(1):38-46. PubMed ID: 20864505
[TBL] [Abstract][Full Text] [Related]
19. A new class of histamine H3 receptor antagonists derived from ligand based design.
Roche O; RodrÃguez Sarmiento RM
Bioorg Med Chem Lett; 2007 Jul; 17(13):3670-5. PubMed ID: 17498953
[TBL] [Abstract][Full Text] [Related]
20. Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases.
Sadek B; Saad A; Sadeq A; Jalal F; Stark H
Behav Brain Res; 2016 Oct; 312():415-30. PubMed ID: 27363923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]